Literature DB >> 2540855

Extranodal noncutaneous lymphoid hyperplasias represent a continuous spectrum of B-cell neoplasia: demonstration by molecular genetic analysis.

D M Knowles1, E Athan, A Ubriaco, L McNally, G Inghirami, R Wieczorek, M Finfer, F A Jakobiec.   

Abstract

We investigated 16 lymphoid proliferations occurring in the ocular adnexa, salivary glands, breast, and thyroid gland and satisfying the histopathologic and immunophenotypic criteria of benign lymphoid hyperplasia for the presence of clonal rearrangements of the antigen receptor, c-myc, bcl-1, and bcl-2 genes and Epstein-Barr virus (EBV) DNA sequences. Each of these 16 extranodal, noncutaneous lymphoid neoplasms exhibited clonal immunoglobulin heavy and/or light chain and lacked T-cell receptor (TCR) beta-chain gene rearrangements. The patterns of immunoglobulin gene rearrangements included solitary and multiple barely perceptible to faint bands, solitary clear and definite bands, and solitary high-intensity bands superimposed on a background of multiple less-intense bands. Three ocular adnexal lymphoid neoplasms exhibited bcl-1 or bcl-2 gene rearrangements. None of the 16 lymphoid neoplasms contained EBV DNA sequences. Two patients developed a histopathologically confirmed malignant lymphoma in an extranodal site. None of the remaining 14 patients developed additional lymphoid neoplasms during a mean follow-up period of 30 months, despite conservative therapy. These results demonstrate that extranodal, noncutaneous lymphoid neoplasms meeting the histopathologic and immunophenotypic criteria for benign lymphoid hyperplasia frequently contain occult monoclonal and oligoclonal B-cell populations representing a continuous and progressive spectrum of B-cell neoplasia up to and including malignant lymphoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540855

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Reactive and neoplastic lymphocytes in human bone marrow: morphological, immunohistological, and molecular biological investigations on biopsy specimens.

Authors:  S M Kröber; H P Horny; A Greschniok; E Kaiserling
Journal:  J Clin Pathol       Date:  1999-07       Impact factor: 3.411

2.  Molecular-genetic analysis of ocular adnexal benign lymphoid hyperplasias by a two-step polymerase-chain-reaction.

Authors:  Y Takano; M Okudaira
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  The bcl-2 gene translocation is undetectable in Hodgkin's disease by Southern blot hybridization and polymerase chain reaction.

Authors:  E Athan; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

4.  bcl-1 rearrangement. Frequency and clinical significance among B-cell chronic lymphocytic leukemias and non-Hodgkin's lymphomas.

Authors:  E Athan; D R Foitl; D M Knowles
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

5.  An overview of ocular adnexal lymphoid tumors.

Authors:  F A Jakobiec; D M Knowles
Journal:  Trans Am Ophthalmol Soc       Date:  1989

6.  Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival.

Authors:  C Jenkins; G E Rose; C Bunce; J E Wright; I A Cree; N Plowman; S Lightman; I Moseley; A Norton
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

7.  Polymerase chain reaction (PCR) detection of B cell clonality in Sjögren's syndrome patients: a diagnostic tool of clonal expansion.

Authors:  L M Guzmán; D Castillo; S O Aguilera
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

8.  Clonal B cell populations in a minority of patients with Hashimoto's thyroiditis.

Authors:  A Saxena; E C Alport; O Moshynska; R Kanthan; M A Boctor
Journal:  J Clin Pathol       Date:  2004-12       Impact factor: 3.411

9.  A case of reactive plasmacytosis mimicking multiple myeloma in a patient with primary Sjogren's syndrome.

Authors:  Jisoo Lee; Ji-Eun Chang; Young-Joo Cho; Woon Seop Han
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.